Weight-loss jabs ease sleep apnoea, but they will not replace the mask

Obstructive sleep apnoea is strongly tied to excess weight, and weight reduction is recommended for all overweight and obese patients with the condition. CPAP remains the mainstay of treatment, but it manages the airway night by night rather than tackling the weight that often drives the problem. GLP-1 receptor agonist drugs have demonstrated clear benefits for weight reduction, which raises an obvious question: do they also improve the apnoea itself? This review set out to pool every randomised trial that has tested that idea in people with moderate to severe disease.

The authors systematically searched electronic databases and trial registries up to February 10, 2025 for randomised controlled trials comparing GLP-1 receptor agonist based therapies against control in adults with moderate to severe obstructive sleep apnoea. Six trials met the criteria, covering 1,069 participants in total. Four of the trials evaluated liraglutide and two evaluated tirzepatide. The outcomes assessed included the apnoea-hypopnoea index, body weight, the oxygen desaturation index, minimum oxygen saturation, systolic and diastolic blood pressure, and adverse events.

Compared with control, the drugs reduced the apnoea-hypopnoea index by 9.99 events per hour and body weight by 9.68 kg. Systolic blood pressure fell by 4.77 mmHg and diastolic blood pressure by 1.41 mmHg. Two things did not move: neither the oxygen desaturation index nor minimum oxygen saturation showed a significant difference, which matters because oxygen dips are part of what makes apnoea harmful. The therapies did not increase the risk of adverse events, though the trials disagreed substantially with each other on the size of the benefits, which limits confidence in the exact pooled figures.

The finding fits the long-standing logic that losing weight improves sleep apnoea, and it extends individual trial results by pooling liraglutide and tirzepatide studies together. The authors are explicit that the evidence supports a potential role for these drugs within comprehensive apnoea management rather than as replacements for CPAP. Open questions remain: why the apnoea severity score improved while oxygen measures did not, whether the two drugs differ meaningfully from each other, and how durable the benefit is. The large disagreement between trials means the true average effect is still uncertain.

If you have moderate to severe sleep apnoea and carry extra weight, this is a reason to see the new weight-loss drugs as potentially relevant to your condition, not just your waistline. It is equally a reason not to view them as an escape route from CPAP: the review's own authors say they are no substitute, and the oxygen measures did not clearly improve. Any decision about these medicines belongs with a doctor who knows your case. The honest summary is that apnoea severity fell alongside weight, which is encouraging rather than conclusive.